The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Bonanad, Clara; García‐Blas, Sergio; Tarazona-Santabalbina, Francisco José; Sanchís, Juan; Bertomeu-González, Vicente; Fácila, Lorenzo; Ariza, Albert; Núñez, Julio; Cordero, Alberto

doi:10.1016/j.jamda.2020.05.045

Cited by 613 publications

(560 citation statements)

References 15 publications

Supporting

Mentioning

468

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent with previous literature that points out a special vulnerability of frail older adults. Mortality is less than 1.1% in patients aged <50 years and it increases exponentially after that age up to around 30% [27], especially in frail older adults who have the highest proportion of severe cases of COVID-19 and fatal outcomes [28]. Thus, this result validates the consistency of our cohort and of our main results, notably the protective effect of the regular intake of vitamin D supplements on COVID-19 outcomes.…”

Section: Discussionsupporting

confidence: 88%

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Annweiler

Corvaisier

Gautier³

et al. 2020

Nutrients

235

255

View full text Add to dashboard Cite

Background. The objective of this quasi-experimental study was to determine whether bolus vitamin D supplementation taken either regularly over the preceding year or after the diagnosis of COVID-19 was effective in improving survival among hospitalized frail elderly COVID-19 patients. Methods. Seventy-seven patients consecutively hospitalized for COVID-19 in a geriatric unit were included. Intervention groups were participants regularly supplemented with vitamin D over the preceding year (Group 1), and those supplemented with vitamin D after COVID-19 diagnosis (Group 2). The comparator group involved participants having received no vitamin D supplements (Group 3). Outcomes were 14-day mortality and highest (worst) score on the ordinal scale for clinical improvement (OSCI) measured during COVID-19 acute phase. Potential confounders were age, gender, functional abilities, undernutrition, cancer, hypertension, cardiomyopathy, glycated hemoglobin, number of acute health issues at admission, hospital use of antibiotics, corticosteroids, and pharmacological treatments of respiratory disorders. Results. The three groups (n = 77; mean ± SD, 88 ± 5years; 49% women) were similar at baseline (except for woman proportion, p = 0.02), as were the treatments used for COVID-19. In Group 1 (n = 29), 93.1% of COVID-19 participants survived at day 14, compared to 81.2% survivors in Group 2 (n = 16) (p = 0.33) and 68.7% survivors in Group 3 (n = 32) (p = 0.02). While considering Group 3 as reference (hazard ratio (HR) = 1), the fully-adjusted HR for 14-day mortality was HR = 0.07 (p = 0.017) for Group 1 and HR = 0.37 (p = 0.28) for Group 2. Group 1 had longer survival time than Group 3 (log-rank p = 0.015), although there was no difference between Groups 2 and 3 (log-rank p = 0.32). Group 1, but not Group 2 (p = 0.40), was associated with lower risk of OSCI score ≥5 compared to Group 3 (odds ratio = 0.08, p= 0.03). Conclusions. Regular bolus vitamin D supplementation was associated with less severe COVID-19 and better survival in frail elderly.

show abstract

Section: Discussionsupporting

confidence: 88%

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Annweiler

Corvaisier

Gautier³

et al. 2020

Nutrients

235

255

View full text Add to dashboard Cite

show abstract

“…A meta-analysis including COVID-19 patients from different countries showed that age is a determining factor on mortality, especially above 60 years of age [19]. Although susceptibility to infection may be similar in different age ranges, studies suggest that susceptibility to symptomatic infection increases with age, possibly related to immunosenescence and unregulated immune response [20].…”

Section: Discussionmentioning

confidence: 99%

On the Analysis of Mortality Risk Factors for Hospitalized COVID-19 Patients: a Data-driven Study Using the Major Brazilian Database

Souza

Hojo-Souza

Batista

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Brazil became the epicenter of the COVID-19 epidemic in a brief period of a few months after the first officially registered case. The knowledge of the epidemiological/clinical profile and the risk factors of Brazilian COVID-19 patients can assist in the decision making of physicians in the implementation of early and most appropriate measures for poor prognosis patients. However, these reports are missing. Here we present a comprehensive study that addresses this demand. Methods: This data-driven study was based on the Brazilian Ministry of Health Database (SIVEP-Gripe, 2020) regarding notified cases of hospitalized COVID-19 patients during the period from February 26 to August 10, 2020. Demographic data, clinical symptoms, comorbidities and other additional information of patients were analyzed. Results: The hospitalization rate was higher for male gender (56.56%) and for older age patients of both sexes. Overall, the mortality rate was quite high (41.28%) among hospitalized patients, especially those over 60 years of age. Most prevalent symptoms were cough, dyspnoea, fever, low oxygen saturation and respiratory distress. Heart disease, diabetes, obesity, kidney disease, neurological disease, and pneumopathy were the most prevalent comorbidities. A high prevalence of hospitalized COVID-19 patients with heart disease (65.7%) and diabetes (53.55%) and with a high mortality rate of around 50% was observed. The ICU admission rate was 39.37% and of these 62.4% died. 24.4% of patients required invasive mechanical ventilation (IMV), with high mortality among them (82.98%). The main mortality risk predictors were older age and IMV requirement. In addition, socioeconomic conditions have been shown to significantly influence the disease outcome, regardless of age and comorbidities. Conclusion: Our study provides a comprehensive overview of the hospitalized Brazilian COVID-19 patients profile and the mortality risk factors. The analysis also evidenced that the disease outcome is influenced by multiple factors, as unequally affects different segments of population.

show abstract

“…Age is known to be an important determinant of outcome following SARS-CoV-2 infection in the general population, with an increase in mortality after age 50 years ( Bonanad, C et al, J Am Med Dir Assoc . 2020 ).…”

mentioning

confidence: 99%

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

McClenaghan

Cosgriff

Brownlee

et al. 2020

Journal of Cystic Fibrosis

101

View full text Add to dashboard Cite

Highlights We report 181 people with CF from 19 countries diagnosed with SARS-CoV-2 Spectrum of outcomes observed was similar to that seen in the general population 11 people were admitted to intensive care and 7 died Three of the people who died had received an organ transplant Lower lung function and having been transplanted may be linked to hospitalisation

show abstract

The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Abstract: JAMDA jo u rn a l h o m e p a g e : w w w . j a m d a . c o m

Cited by 613 publications

References 15 publications

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study

On the Analysis of Mortality Risk Factors for Hospitalized COVID-19 Patients: a Data-driven Study Using the Major Brazilian Database

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

Contact Info

Product

Resources

About